Medtronic launches new heart valve repair ring worldwide
This article was originally published in Clinica
Medtronic has launched the Contour 3D annuloplasty ring, intended for the treatment of tricuspid valve disease, worldwide. It is approved in the US, Europe and several other countries. The ring is designed to treat tricuspid dilation, a progressive disease that leads to severe tricuspid regurgitation, which occurs when the tricuspid valve leaflets do not close properly, allowing blood to flow opposite of the intended direction. The Contour 3D is implanted surgically to restore normal valve function by remodelling the natural valve’s shape and size.
You may also be interested in...
Dr Noam Emanuel is the founder and chief technology officer of Ness Ziona, Israel-based drug delivery firm PolyPid. The 15-strong firm, established in 2008, has developed an encapsulation technology which allows the precise targeting of drug release.
Mesoblast has received the all-clear from the US FDA to start a Phase III clinical trial for bone marrow regeneration in patients with blood cancers. The study will be conducted together with Mesoblast's strategic alliance partner, Cephalon, which will fund the trial.
Mesoblast has received the green light from the US FDA to begin a Phase II trial of its proprietary adult mesenchymal precursor cell (MPC) product for the treatment of degenerative disc disease, a major cause of chronic low back pain.